Glide Technologies has announced that they have successfully completed a pre-clinical proof-of-concept study with its novel solid dose formulation of exenatide, a GLP-1 agonist for the treatment of Type 2 diabetes.
Results from the pharmacokinetic study show there was no statistical difference (p<0.05) between Glide’s solid dose formulation and the clinical dose of Byetta (exenatide 10 mcg), the currently marketed liquid product.
Glide’s solid dose formulations are designed to be delivered using the company’s self-administered, user-friendly, needle-free SDI injector.
The technology has multiple advantages over current marketed liquid peptide products, which are needle administered and require cold chain logistics and refrigeration at home.
In particular, the technology has the potential to significantly improve patient compliance, which is important where self-administered injections are required, such as diabetes.
The results follow previous successful proof-of-concept studies with Glide’s novel solid dose formulations of currently marketed liquid products Forteo/Forsteo (teriparatide) and Sandostatin (octreotide).
Consequently, Glide’s solid dose formulation technology has achieved equivalence across a series of peptide products, demonstrating flexibility of the platform to deliver this important class of therapeutics.
Glide CEO Dr Mark Carnegie-Brown said: "These encouraging results follow positive equivalence data with Glide’s octreotide SDI and teriparatide SDI and clearly demonstrate the flexibility of our solid dose technology in delivering therapeutic peptides.
"The Glide SDI has important advantages over current liquid products, particularly for self-administered treatments where patient-focused ease-of-use and compliance are key."